Abstract:Klebsiella pneumoniae presents as two circulating pathotypes: classical K . pneumoniae (c Kp) and hypervirulent K . pneumoniae (hv Kp ). Classical isolates are considered urgent threats due to their antibiotic resistance profiles, while hv Kp isolates have historically been antibiotic susceptible. Recently, however, increased rates of antibiotic resistance have been observed in both hv Kp and c Kp , further underscoring the need for preventive and effective immunotherapies. Two distinct surface polysaccharides have gained traction as vaccine candidates against K . pneumoniae : capsular polysaccharide and the O-antigen of lipopolysaccharide. While both targets have practical advantages and disadvantages, it remains unclear which of these antigens included in a vaccine would provide superior protection against matched K . pneumoniae strains. Here, we report the production of two bioconjugate vaccines, one targeting the K2 capsular serotype and the other targeting the O1 O-antigen. Using murine models, we investigated whether these vaccines induced specific antibody responses that recognize K2:O1 K . pneumoniae strains. While each vaccine was immunogenic in mice, both c Kp and hv Kp strains exhibited decreased O-antibody binding in the presence of capsule. Further, O1 antibodies demonstrated decreased killing in serum bactericidal assays with encapsulated strains, suggesting that the presence of K . pneumoniae capsule blocks O1-antibody binding and function. Finally, the K2 vaccine outperformed the O1 vaccine against both c Kp and hv Kp in two different murine infection models. These data suggest that capsule-based vaccines may be superior to O-antigen vaccines for targeting hv Kp and some c Kp strains, due to capsule blocking the O-antigen. Currently there are no licensed vaccines targeting K . pneumoniae , but several are in development. Two prominent K . pneumoniae surface polysaccharides (capsule and O-antigen) represent attractive vaccine targets; however, the relative efficacy of these potential vaccines against K . pneumoniae strains has not been directly compared. To inform future vaccine development, we evaluate two bioconjugate vaccines (targeting either capsule or O-antigen) demonstrating that each are immunogenic in murine models. However, we find that K . pneumoniae capsule largely inhibits recognition by antibodies raised against O-antigen. Further, we demonstrate that a capsule-based vaccine outperforms an O-antigen vaccine against both c Kp and hv Kp in murine models of pneumonia and bacteremia, suggesting that capsule-based vaccines offer superior protection from some K . pneumoniae infections.

Protective Efficacy of DNA Vaccines Encoding Outer Membrane Protein A and OmpK36 of Klebsiella pneumoniae in Mice

Evaluation of Recombinant Multi-Epitope Outer Membrane Protein-Based Klebsiella pneumoniae Subunit Vaccine in Mouse Model

A conserved outer membrane protein as an effective vaccine candidate from Vibrio alginolyticus

Identification and Evaluation of Recombinant Outer Membrane Proteins as Vaccine Candidates Against Klebsiella pneumoniae

Characterization of Ompk, Gapdh and Their Fusion Ompk-Gapdh Derived from Vibrio Harveyi Outer Membrane Proteins: Their Immunoprotective Ability Against Vibriosis in Large Yellow Croaker (pseudosciaena Crocea)

Co-immunization with DNA vaccines encoding yidR and IL-17 augments host immune response against Klebsiella pneumoniae infection in mouse model

In silico and in vivo Investigations of the Immunoreactivity of Klebsiella pneumoniae OmpA Protein as a Vaccine Candidate

Immunogenic characteristics of the outer membrane phosphoporin as a vaccine candidate against Klebsiella pneumoniae

Vaccination with OprB porin, and its epitopes offers protection against A. baumannii infections in mice

Intradermal Immunization with Heat-Killed Klebsiella pneumoniae Leading to the Production of Protective Immunoglobulin G in BALB/c Mice

[The Study for the Immuno-Protection of E. Coli O157:H7 Outer Membrane Protein].

The Immune Response and Protective Efficacy of Vaccination with Oral Microparticle Aeromonas Sobria Vaccine in Mice

Relative Immunogenicity and Protection Potential of Candidate Yersinia Pestis Antigens Against Lethal Mucosal Plague Challenge in Balb/C Mice.

Capsular polysaccharide inhibits vaccine-induced O-antigen antibody binding and function across both classical and hypervirulent K2:O1 strains of Klebsiella pneumoniae

A DNA Vaccine Producing LcrV Antigen in Oligomers is Effective in Protecting Mice from Lethal Mucosal Challenge of Plague

A New Live Auxotrophic Vaccine Induces Cross-Protection against Klebsiella pneumoniae Infections in Mice

Immunization with Pseudomonas aeruginosa outer membrane vesicles stimulates protective immunity in mice

Subcutaneous Immunization with Fusion Protein DnaJ-ΔA146Ply without Additional Adjuvants Induces both Humoral and Cellular Immunity against Pneumococcal Infection Partially Depending on TLR4

Putative novel outer membrane antigens multi-epitope DNA vaccine candidates identified by Immunoinformatic approaches to control Acinetobacter baumannii

Nanoparticle reinforced bacterial outer-membrane vesicles effectively prevent fatal infection of carbapenem-resistant Klebsiella pneumoniae

Employing Escherichia coli-derived outer membrane vesicles as an antigen delivery platform elicits protective immunity against Acinetobacter baumannii infection